REG - Aptamer Group PLC - New contract with top five pharma company

AptamerAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251104:nRSD0162Ga&default-theme=true

RNS Number : 0162G  Aptamer Group PLC  04 November 2025

4 November 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

 Aptamer secures major repeat business with top 5 pharmaceutical partner

New contract value of up to £617,000

Contract value visibility for the current financial year of £1.75 million

 

Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic
binders for the life sciences industry, is pleased to announce that it has
secured a new contract with a top five pharmaceutical company, with a value of
up to £617,000.

 

This new contract is the third project with this pharmaceutical company and
demonstrates a strong validation of the Optimer® platform, which continues to
deliver tools to support their key therapeutic developments. Having
demonstrated superior performance of Optimer® binders over traditional
antibodies in the Group's previous project, the partner is now scaling the
relationship with a multi-target programme.

 

Under the agreement, Aptamer will develop Optimer® binders against three key
drug targets and provide critical support for ELISA assay development. These
tools will enable the partner to validate drug candidates and may also be used
to analyse patient samples during clinical trials, potentially leading to
clinical diagnostic development.

 

Importantly, Aptamer retains full intellectual property rights to all
developed Optimers, creating potential for future licensing revenues across
each of the three targets as these binders prove their value in commercial
applications.

 

Following a period of strong pipeline conversion during the first four months
of the financial year, Aptamer has signed contract value of £1.75 million,
which is a 46% increase compared to the £1.2 million reported at the same
time last year. This gives the management team confidence in the delivery of
continued growth for FY26, building on that achieved during FY25.

 

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, said: "This
contract represents significant commercial validation and increasing traction
of our Optimer® technology platform. The decision by a top five
pharmaceutical partner to commission this large-scale, multi-target programme
follows the successful completion of a proof-of-concept project where we
demonstrated the superior performance of our Optimers compared to traditional
antibodies and our ability to successfully deliver binders, to support our
customers with their critical projects.

 

This means the Group now has signed contract value of £1.75 million for this
financial year, with eight months of the financial year still remaining. As
such, we are well-positioned to build on last year's performance and deliver
sustained revenue growth. We continue to build a robust foundation of repeat
business with leading pharmaceutical partners, converting our commercial
pipeline into long-term value for shareholders."

 

-Ends -

 

For further information, please contact: 

 

 Aptamer Group plc                                                  +44 (0) 1904 217 404  

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser                +44 (0) 20 3368 3550  

 Andrew Emmott  
 Turner Pope Investments (TPI) Limited - Broker                     +44 (0) 20 3657 0050  

 James Pope / Andrew Thacker  
 Northstar Communications Limited - Investor Relations              +44 (0) 113 730 3896

 Sarah Hollins 

 

About Aptamer Group

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to

https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUPGRWGUPAPPW



            Copyright 2019 Regulatory News Service, all rights reserved